Nvidia CEO Jensen Huang announced significant partnerships with Japanese robotics companies Fanuc and Yaskawa Electric during his recent visit to Tokyo. Huang emphasized that artificial intelligence will make robots “smart, easily adaptable and accessible”. The revelation led to a slight increase in Nvidia’s stock, which rose by 0.33% as the news spread.
The collaborations aim to enhance developments in both robotics and healthcare. In health technology, several prominent pharmaceutical companies, including Astellas and Daiichi Sankyo, are already using Nvidia’s BioNeMo platform to accelerate drug discovery processes. Astellas has fully integrated various BioNeMo NIM microservices while Ono Pharmaceuticals is leveraging specific microservices for expedited research.
Further, major names in medical imaging, Canon and Fujifilm, have introduced next-generation CT systems reliant on Nvidia GPUs. This marks a first for Japan's medical sector, reflecting the country’s commitment to combining tech advancements with healthcare innovation.
Huang's visit aligns with rising forecasts in the semiconductor sector, specifically from ASML and TSMC, which is expected to report its fifth consecutive quarter of record earnings due to increasing AI demand. The momentum in partnerships shows Japan's crucial role in implementing AI technologies across various industrial sectors, ranging from robotics to pharmaceuticals. Nvidia continues to position itself as a key player in this collaboration landscape.
This material is for informational purposes only and does not constitute financial advice.
